Abstract
Background
The goal of the present study was to make our medical practice evidence-based for patients with parathyroid carcinoma.
Methods
We posed six clinical questions relevant to the management of parathyroid cancer. A comprehensive search and critical appraisal of the literature was then carried out.
Results
Most of the literature retrieved was retrospective in design and differed in the definition of carcinoma. The distinction between unequivocal and equivocal carcinoma (or atypical adenoma) was not always made for the study populations. None of the studies indicated reproducibility of outcome measures. Of the histopathological features described in the literature based on the description of Schantz and Castleman, capsular/vascular invasions and trabecular growth pattern were the most specific, and fibrous bands were the most sensitive. None of the patients with “atypical adenoma” developed recurrence, whereas 25% of those with “equivocal carcinoma” did. Mutations in HRPT2, the gene responsible for hereditary hyperparathyroidism with jaw-tumor syndrome, were strongly associated with sporadic parathyroid carcinoma. Severe hypercalcemia and its related clinical symptoms, extremely high levels of parathyroid hormone, osteitis fibrosa cystica, a palpable neck mass, and a relatively large depth–width ratio on ultrasonography, are the important features of parathyroid carcinoma. Disease-specific survival rates reported in the literature were varied, reflecting the differences in the definitions of carcinoma, study populations, and interventions.
Conclusions
To establish valid evidence for patient management in the future, a collaboration of endocrine specialists is essential to conduct well-designed clinical studies for this rare disease.
Similar content being viewed by others
References
Sackett DL (2000) The sins of expertness and a proposal for redemption. BMJ 320:1283
Straus S, Richardson WS, Glasziou P (2005) Evidence-based medicine: how to practice and teach EBM, 3rd edn. Elsevier, Edinburgh
Haynes RB, Sackett DL, Guyatt GH et al (2006) Clinical epidemiology: how to do clinical practice research, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
Fletcher RH, Fletcher SW (2005) Clinical epidemiology: the essentials, 4th edn. Lippincott Williams & Wilkins, Philadelphia
Feinstein AR (1985) Clinical epidemiology: the architecture of clinical research. W. B. Saunders, Philadelphia
Sackett DL (1989) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95((suppl)):2S–4S
Cook TD, Campbell DT (1979) Quasi-experimentation: design & analysis issues for field settings. Boston, Houghton Mifflin, pp 37–94
Haynes RB, Wilczynski NL (2004) Optimal search strategies for retrieving scientifically strong studies of diagnosis from Medline: analytical survey. BMJ 328:1040–1044
Haynes RB, McKibbon KA, Wilczynski NL et al (2005) Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 330:1179–1184
Shane E (2001) Parathyroid carcinoma. J Clin Endocrinol Metab 86:485–493
DeLellis RA (1993) Tumors of the parathyroid glands. Atlas of Tumor Pathology. 3rd series, fascicle 6. Armed Forces Institute of Pathology, Washington, DC
DeLellis RA (2005) Parathyroid carcinoma: an overview. Adv Anat Pathol 12:53–61
Altenahr E, Saeger W (1973) Light and electron microscopy of parathyroid carcinoma: report of three cases. Virchows Arch A Pathol Pathol Anat 360:107–122
Ebner S, Emerson CH (1993) Documentation of parathyroid carcinoma fifteen years after resection of a parathyroid “adenoma”. Clin Endocrinol 38:659–661
Bichel P, Thomsen OF, Askjaer AA et al (1980) Light and electron microscopic investigation of parathyroid carcinoma during dedifferentiation. Survey and study of a case. Virchows Arch A Pathol Anat Histol 386:363–370
Hakaim AG, Esselstyn CB (1993) Parathyroid carcinoma: 50-year experience at the Cleveland Clinic Foundation. Cleve Clin J Med 60:331–335
McKeown PP, McGarity WC, Sewell CW (1984) Carcinoma of the parathyroid gland: is it overdiagnosed? A report of three cases. Am J Surg 147:292–298
Schantz A, Castleman B (1973) Parathyroid carcinoma: a study of 70 cases. Cancer 31:600–605
Snover DC, Foucar K (1981) Mitotic activity in benign parathyroid disease. Am J Clin Pathol 75:345–347
Smith JF, Coombs RR (1984) Histological diagnosis of carcinoma of the parathyroid gland. J Clin Pathol 37:1370–1378
Trigonis C, Cedermark B, Willems J et al (1984) Parathyroid carcinoma—problems in diagnosis and treatment. Clin Oncol 10:11–19
Lillemoe KD, Dudley NE (1985) Parathyroid carcinoma: pointers to successful management. Ann R Coll Surg Engl 67:222–224
Levin KE, Galante M, Clark OH (1987) Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 101:649–660
Evans HL (1991) Criteria for diagnosis of parathyroid carcinoma: a critical study. Surg Pathol 4:244–265
Bondeson L, Sandelin K, Grimelius L (1993) Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 17:820–829
Sheehan JJ, Hill AD, Walsh MF et al (2001) Parathyroid carcinoma: diagnosis and management. Eur J Surg Oncol 27:321–324
Dotzenrath C, Goretzki PE, Sarbia M et al (2001) Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol 27:383–389
Stojadinovic A, Hoos A, Nissan A et al (2003) Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 34:54–64
Busaidy NL, Jimenez C, Habra HA et al (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26:716–726
Bergero N, Pompa R, Sacerdote C et al (2005) Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36:908–914
Chow E, Tsang RW, Brierley JD et al (1998) Parathyroid carcinoma: the Princess Margaret Hospital experience. Int J Radiat Oncology Biol Phys 41:569–572
Chang YJ, Mittal V, Remine S et al (2006) Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg 72:419–426
Fujimoto Y, Obara T (1987) How to recognize and treat parathyroid carcinoma. Surg Clin North Am 67:343–357
Obara T, Okamoto T, Kanbe M et al (1997) Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Semin Surg Oncol 13:134–141
Sandelin K, Auer G, Bondeson L et al (1992) Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16:724–731
Fujimoto Y, Obara T, Ito Y et al (1984) Surgical treatment of ten cases of parathyroid carcinoma: importance of an initial en bloc tumor resection. World J Surg 8:392–400
Koea JB, Shaw JHF (1999) Parathyroid cancer: biology and management. Surg Oncol 8:155–165
Dinnen JS, Greenwood RH, Jones JH et al (1977) Parathyroid carcinoma in familial hyperparathyroidism. J Clin Pathol 30:966–975
Kakinuma A, Morimoto I, Nakano Y et al (1994) Familial primary hyperparathyroidism complicated with Wilms’ tumor. Intern Med 33:123–126
Simonds WF, James-Newton LA, Agarwal SK et al (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine 81:1–26
Szabo J, Heath B, Hill VM et al (1995) Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21–q31. Am J Hum Genet 56:944–950
Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–680
Howell VM, Haven CJ, Kahnoski K et al (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet 40:657–663
Shattuck TM, Valimaki S, Obara T et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–1729
Cetani F, Pardi E, Borsari S et al (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89:5583–5591
Krebs LJ, Shattuck TM, Arnold A (2005) HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90:5015–5017
Haven CJ, van Puijenbroek M, Tan MH et al (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol 67:370–376
Obara T, Fujimoto Y, Kanaji Y et al (1990) Flow cytometric DNA analysis of parathyroid tumors: implication of aneuploidy for pathologic and biologic classification. Cancer 66:1555–1562
Lumachi F, Ermani M, Marino F et al (2004) (2004) Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma. Endocr Relat Cancer 11:563–569
Robert JH, Trombetti A, Garcia A et al (2005) Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature. Ann Surg Oncol 12:1–7
Hara H, Igarashi A, Yano Y et al (2001) Ultrasonographic features of parathyroid carcinoma. Endocrine J 48:213–217
Okamoto T, Obara T, Fujimoto Y et al (1991) Preoperative diagnosis of parathyroid carcinoma: quantitative analysis of preoperative information. Endocr Surg 8:401–405 (in Japanese)
Holmes EC, Morton DL, Ketcham AS (1969) Parathyroid carcinoma: a collective review. Ann Surg 169:631–640
Munson ND, Foote RL, Northcutt RC et al (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98:2378–2384
Rawat N, Khetan N, Williams W et al (2005) Parathyroid carcinoma. Br J Surg 92:1345–1353
Iihara M, Okamoto T, Suzuki R et al (2007) Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery 142:936–943
Obara T, Okamoto T, Ito Y et al (1993) Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery 114:1040–1049
Flye MW, Brennan MF (1981) Surgical resection of metastatic parathyroid carcinoma. Ann Surg 193:425–435
Wang C, Gaz RD (1985) Natural history of parathyroid carcinoma: diagnosis, treatment, and results. Am J Surg 149:522–527
Kebebew E, Arici C, Duh QY et al (2001) Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878–885
Hundley JC, Albertson DA, Bradley RF et al (2003) Resection of pulmonary metastasis from parathyroid carcinoma. Am Surg 69:779–783
Collins MT, Skarulis MC, Bilezikian JP et al (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083–1088
Silverberg SJ, Rubin MR, Faiman C et al (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803–3808
Shane E, Jacobs TP, Siris ES et al (1982) Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate. Am J Med 72:939–944
Jüngst D (1984) Disodium clodronate effective in management of severe hypercalcemia caused by parathyroid carcinoma. Lancet 2:1043
Vega EM, Mautalen CA (1991) Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma. Medicina 51:106–110
Newrick PG, Braatvedt GD, Webb AJ et al (1994) Prolonged remission of hypercalcemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 70:231–232
Szmuilowicz ED, Utiger RD (2006) A case of parathyroid carcinoma with hypercalcemia responsive to cinacalet therapy. Nat Clin Pract Endocrinol Metab 2:291–296
Goepfert H, Smart CR, Rochlin DB (1966) Metastatic parathyroid carcinoma and hormonal chemotherapy: case report and response to hexestrol. Ann Surg 164:917–920
Hill CS, Ouais SG, Leiser AE (1972) Long-term administration of calcitonin for hypercalcemia secondary to recurrent parathyroid carcinoma. Cancer 29:1016–1020
Singer FR, Neer RM, Murray TM et al (1970) Mithramycin treatment of intractable hypercalcemia due to parathyroid carcinoma. N Engl J Med 283:634–636
Warrell RP Jr, Issacs M, Alcock NW et al (1987) Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma. Ann Intern Med 107:683–686
Calandra DB, Chejfec G, Foy BK et al (1984) Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 96:1132–1136
Bukowski RM, Sheeler L, Cunningham J et al (1984) Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 144:399–400
Anderson BJ, Samaan NA, Vassilopoulou-Sellin R et al (1983) Parathyroid carcinoma: features and difficulties in diagnosis and management. Surgery 94:906–915
Wynne AG, van Heerden J, Carney A et al (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 71:197–205
Schott M, Feldkamp J, Schattenberg D et al (2000) Induction of cellular immunity in parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300–306
Bradwell AR, Harvey TC (1999) Control of hypercalcemia of parathyroid carcinoma by immunisation. Lancet 353:370–373
Betea D, Bradwell AR, Harvey TC et al (2004) Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413–3420
Acknowledgments
This work was supported in part by a Grant-in-aid for Cancer Research (17–21) from the Ministry of Health, Labour and Welfare of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Okamoto, T., Iihara, M., Obara, T. et al. Parathyroid Carcinoma: Etiology, Diagnosis, and Treatment. World J Surg 33, 2343–2354 (2009). https://doi.org/10.1007/s00268-009-9999-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-009-9999-0